Skip to contentS
Starling Oncology, Inc.
S
STLNStarling Oncology, Inc. Q1 2023 · 10-Q
Revenue$76.19M$76.19M+38.1% vs Q1 2022 Net Income-$30.00M-$30.00MN/M vs Q1 2022 EPS Diluted-$0.33-$0.33N/M vs Q1 2022 Operating Income-$32,867,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
Free Cash Flowderived-$17,291,000N/M Margins · derivedOperating margin-43.1%−9.7 pt vs Q1 2022
Net margin-39.4%−74.3 pt vs Q1 2022
ended Mar 31, 2023 · filed May 10, 2023 · 40 d after period end